Skip to content
EN
فا
EN
فا
COMPANY
RESPONSIBILITY
OUR PARTNERS
ABOUT US
PRODUCTS
NEWS
Actero Support
Physician
Nurse Support
Patient Support
Adverse Drug Reactions
CONTACT
CONTACT US
JOIN US
COMPANY
RESPONSIBILITY
OUR PARTNERS
ABOUT US
PRODUCTS
NEWS
Actero Support
Physician
Nurse Support
Patient Support
Adverse Drug Reactions
CONTACT
CONTACT US
JOIN US
Search
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
Leave a Reply
Your email address will not be published.
Required fields are marked
*
Comment
*
Name
Email
Website